Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ia/b Double-blind, Placebo-controlled, Dose Escalating Safety Study of Detoxified Shigella Flexneri 2a Artificial Invasin Complex (InvaplexAR-Detox) Vaccine Formulated with and Without DmLT Adjuvant Given Intramuscularly to Healthy Adults in the Netherlands and Zambia

NCT05961059 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT05961059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05961059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ia/b Double-blind, Placebo-controlled, Dose Escalating Safety Study of Detoxified Shigella Flexneri 2a Artificial Invasin Complex (InvaplexAR-Detox) Vaccine Formulated with and Without DmLT Adjuvant Given Intramuscularly to Healthy Adults in the Netherlands and Zambia
Lead sponsor
Leiden University Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
October 10, 2024
Completion date
May 31, 2025
Enrollment
85 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bacillary dysentery, shigellosis